Renal Cell Carcinoma Metastatic

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS approval · 2012-03-09
Clinical Trial Update: Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Pfizer's sunitinib (SU011248) has been approved for marketing for use in cytokine-refractory metastatic renal cell carcinoma.